VolitionRx director awarded 12,000 shares in RSU vest
VolitionRx Ltd director Phillip Barnes reported acquiring 12,000 shares of common stock on January 22, 2026 at a price of $0, increasing his direct holdings to 67,368 shares.
Rhea-AI Filing Summary
VolitionRx Ltd director Phillip Barnes reported acquiring 12,000 shares of common stock on January 22, 2026 at a price of $0, increasing his direct holdings to 67,368 shares. These shares relate to a grant of 40,000 restricted stock units (RSUs) awarded on March 17, 2025 under the company’s 2024 Stock Incentive Plan.
The RSUs were tied to corporate performance goals and time-based vesting. Only the targets for 12,000 RSUs were achieved; the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested portion is scheduled to vest over three years in equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with one share of common stock delivered for each RSU that ultimately vests.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 12,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. On March 17, 2025, the reporting person was awarded 40,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 4,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did VolitionRx (VNRX) director Phillip Barnes report?
Phillip Barnes, a director of VolitionRx Ltd, reported the acquisition of 12,000 shares of common stock on January 22, 2026 at a price of $0. Following this transaction, he directly beneficially owned 67,368 shares of VolitionRx common stock.
How many VolitionRx (VNRX) RSUs were originally granted to Phillip Barnes?
On March 17, 2025, Phillip Barnes was granted 40,000 restricted stock units (RSUs) under VolitionRx’s 2024 Stock Incentive Plan. These RSUs were subject to both corporate performance goals and time-based vesting conditions.
How many of Phillip Barnes’s VolitionRx RSUs vested and how many were cancelled?
Certain performance goals were achieved, so rights with respect to 12,000 RSUs vested. The rights with respect to the remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.
What is the vesting schedule for Phillip Barnes’s VolitionRx RSUs tied to this Form 4?
The 12,000 RSUs that met performance goals are subject to a 3-year time-based vesting schedule. They vest in three equal installments of 4,000 units on each of March 17, 2026, March 17, 2027, and March 17, 2028.
How do Phillip Barnes’s RSUs convert into VolitionRx (VNRX) common stock?
Upon vesting and settlement of the RSUs, Phillip Barnes will receive one share of VolitionRx common stock for each RSU that has vested. Thus, up to 12,000 shares of common stock may be delivered as the vesting schedule is completed.
AI-generated analysis. How Rhea-AI works. Not financial advice.